AKT1 and lymphoma: Moreover, another study (Yan et al., 2015), found that patients with T cell leukemia/lymphoma showed increase in level of miR-181a and this overexpression was associated with increased AKT phosphorylation and can contribute to chemoresistance in T cell leukemia/lymphoma assuming that miR-181a could be a promising therapeutic target in treating T-cell malignancies resistant to chemotherapy.